J&J Janssen Akeega Gets FDA Approval to Treat Prostate Cancer

 Janssen Pharmaceutical said Friday that the Food and Drug Administration approved Akeega as a treatment for a specific type of prostate cancer.

Akeega, or niraparib and abiraterone acetate, was approved as a treatment for BRCA-positive metastatic castration-resistant prostate cancer, the Johnson & Johnson unit said. About 10% to 15% of patients with mCRPC have BRCA gene alterations, making them more likely to experience poor outcomes and a shorter survival time, the company said.

The approval was based on results from a Phase 3 study. The company said in BRCA-positive patients treated with Akeega plus prednisone, 47% risk reduction was observed for radiographic progression-free survival.

https://www.marketscreener.com/quote/stock/JOHNSON-JOHNSON-4832/news/Janssen-Pharmaceutical-Akeega-Gets-FDA-Approval-to-Treat-Prostate-Cancer-Patients-44595994/